Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2022-09-19 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2022-09-19 English
6-K
Regulatory Filings
2022-09-15 English
BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital
Capital/Financing Update Classification · 98% confidence The document explicitly states it is a "FORM 6-K" filed with the "SECURITIES AND EXCHANGE COMMISSION" for the month of September 2022. Form 6-K is the standard filing used by Foreign Private Issuers to report material information not required to be reported on a schedule 13D or 13G. The content details a significant financing event: entering into an Agreement for the Provision of a Loan Facility of up to $40 million. This type of material corporate financing activity reported on Form 6-K is best classified under the category for financing updates. Among the provided codes, "Capital/Financing Update" (CAP) is the most appropriate fit for reporting the details of a new loan facility agreement.
2022-09-15 English
BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital
Capital/Financing Update Classification · 95% confidence The document is very short (1913 characters) and explicitly states, "Attached hereto is a report on *BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital* *Form_6-K_15-09-2022_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is often filed as an immediate report or falls under general regulatory filings). Since the text is primarily an announcement pointing to an attached or linked document rather than containing the full details of a financing agreement or a comprehensive report, it fits the definition of a Report Publication Announcement (RPA) or, if RPA is not applicable, a general Regulatory Filing (RNS). Given the specific mention of an attached report and the short length, RPA is the most precise fit, as it announces the publication of the underlying filing (which details the financing activity, fitting under CAP, but the *document type* here is the announcement). However, since the content describes a financing agreement ('$40 Million Non-Dilutive Debt Financing Agreement'), the underlying subject matter is 'Capital/Financing Update' (CAP). Since this document is an 'Immediate Report' referencing an attached PDF (Form 6-K), and it is not a standard SEC form like 10-K, it is best classified as a general Regulatory Filing (RNS) or potentially RPA. Given the context of immediate reporting and the reference to an attached PDF, RNS is a strong general category for non-standard immediate reports filed with the ISA/TASE. If the financing aspect is prioritized, CAP is relevant, but the document's *function* is publication announcement. I will classify it as RNS as it is an immediate report filed with the Israeli Securities Authority (ISA) and TASE, which often defaults to RNS when a more specific category like DEF 14A or 10-K is not met, and RPA is usually reserved for announcements about standard periodic reports. The content strongly relates to financing, but the format is a regulatory announcement wrapper.
2022-09-15 English
6-K
Regulatory Filings
2022-09-12 English
BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing used by Foreign Private Issuers to report material information that is made public in their home country or stock exchange, or that is required to be filed with a stock exchange outside the U.S. This type of filing is generally considered a miscellaneous regulatory filing that does not fit into the specific categories like 10-K (Annual Report) or ER (Earnings Release). Since it is a mandatory SEC filing for foreign issuers reporting material events (in this case, an NDA submission), and it doesn't align with the specific definitions provided (like AGM-R, 10-K, ER, IR, etc.), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as the general category for miscellaneous regulatory announcements.
2022-09-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.